Buy Bergolak

- Prevention of postpartum lactation;

Suppression of already established postpartum lactation;

- treatment of disorders associated with hyperprolactinemia, including amenorrhea, oligomenorrhoea, anovulation, galactorrhea;

- Prolactin secretion adenomas of the pituitary gland (micro- and macro-prolactinomas); idiopathic hyperprolactinaemia; Syndrome of empty Turkish saddle in combination with hyperprolactinemia.

The drug is taken orally, with food.

To prevent lactation after childbirth - 1 mg once (2 tab.) On the first day after birth.

To suppress the steady lactation - 0.25 mg (1/2 tab.) 2 times / day every 12 hours for 2 days (total dose - 1 mg).

In order to reduce the risk of orthostatic hypotension in breast-feeding mothers, a single dose of Bergolak should not exceed 0.25 mg.

For the treatment of violations associated with hyperprolactinemia: the recommended initial dose is 0.5 mg per week in a single dose (1 tablet) or in 2 divided doses (for example, 1/2 tablets, for example, on Monday and Thursday). The increase in the weekly dose should be carried out gradually - by 0.5 mg with a monthly interval until the optimal therapeutic effect is achieved. The therapeutic dose is usually 1 mg per week, but can range from 0.25 to 2 mg per week.

The maximum dose for patients with hyperprolactinemia should not exceed 4.5 mg per week.

Depending on the tolerability, a weekly dose of Bergolak can be taken once or divided into 2 or more receptions per week. The division of a weekly dose into several doses is recommended when the drug is administered at a dose of more than 1 mg per week.

The likelihood of developing side effects can be reduced by starting therapy with a low-dose Bergolak (eg, 0.25 mg once a week), followed by a gradual increase until a therapeutic dose is reached. To improve the tolerability of the drug in the occurrence of severe side effects, it is possible to temporarily reduce the dose, followed by a more gradual increase (for example, an increase of 0.25 mg per week every 2 weeks).

The dopamine receptor agonist, the ergoline derivative, inhibits the secretion of prolactin. Stimulates dopamine D2 receptors of lactotrophic cells of the pituitary gland; in high doses has a central dopaminergic effect. Reduces the concentration of prolactin in the blood, restores the menstrual cycle and fertility. By reducing the concentration of prolactin in the blood, the women recover the pulsating secretion of the gonadotropins and release the luteinizing hormone in the middle of the cycle, eliminate the anovulatory cycles and increase the concentration of estrogens in the body, reduce the severity of hypoestrogenic (weight gain, fluid retention, osteoporosis) and hyperandrogenic (acne, hirsutism ) of symptoms.

In men, reduces the hyperprolactinemia-related decrease in libido, impotence (with a decrease in the concentration of prolactin increases the concentration of testosterone), gynecomastia, lactorrhea. The macroadenoma of the pituitary gland and the associated symptoms (headache, disturbance of the fields and visual acuity, functions of the cranial nerves and the anterior lobe of the pituitary gland) are reversed. Reduces the concentration of prolactin in patients with prolactinoma and pseudoprolactinoma (in the latter - without reducing the size of the pituitary adenoma). Reduction in the concentration of prolactin is observed 3 hours after administration and persists for 7-28 days in patients with hyperprolactinemia and 14-21 days - with suppression of postpartum lactation. Reduction in the concentration of prolactin occurs within 2-4 weeks of treatment.